|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/12 | (2006.01) |
| A61K2039/545 | (2013.01) | ||
| A61P 31/14 | (2006.01) | ||
| A61K2039/55 | (2013.01) | ||
| C12N2760/18634 | (2013.01) | ||
| A61K 39/12 | (2013.01) | ||
| A61P 31/14 | (2018.01) | ||
| A61K 39/155 | (2013.01) | ||
| A61K2039/53 | (2013.01) | ||
| A61K2039/55505 | (2013.01) | ||
| A61K2039/55555 | (2013.01) | ||
| A61K2039/55566 | (2013.01) | ||
| A61K2039/575 | (2013.01) | ||
| C12N2760/18534 | (2013.01) | ||
| C12N2760/18571 | (2013.01) |
| (11) | Number of the document | 3527224 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19165302.1 |
| Date of filing the European patent application | 2012-01-26 | |
| (97) | Date of publication of the European application | 2019-08-21 |
| (45) | Date of publication and mention of the grant of the patent | 2025-02-26 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201161436355 P | 2011-01-26 | US |
| (72) |
DORMITZER, Philip, R. , US
|
| (73) |
GlaxoSmithKline Biologicals S.A. ,
Rue de l'Institut, 89, 1330 Rixensart,
BE
|
| (54) | RSV IMMUNIZATION REGIMEN |
| RSV IMMUNIZATION REGIMEN |